Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Click here for more prescribing information
